Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
News & insights
News: 07 JANUARY 2020
A&O has marked the end of Q4 2019 with a stellar performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.Read more
Publications: 29 NOVEMBER 2019
As more countries liberalise their cannabis policies, there has been a rapid increase in the number of registered IP rights as competitors seek to establish their places in the market.Read more
Publications: 04 OCTOBER 2019
A&O has marked the end of Q3 2019 with an outstanding performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.Read more